Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
These findings suggest that MBS was associated with more weight loss at lower ongoing costs compared with GLP-1 RAs in class II and III obesity. Further study is needed to determine if MBS should still be considered the last resort in treating obesity.
Authors
- Shannon B. Richards (ORCID: https://orcid.org/0000-0002-6278-8388)
- Tyson S. Barrett (ORCID: https://orcid.org/0000-0002-2137-1391)
- Keith LeJeune
- Juliane Hafermann (ORCID: https://orcid.org/0009-0004-4595-7794)
- George M. Eid
Institutions
- Allegheny Health Network (US)
- Highmark Blue Cross Blue Shield (US)
Publication Details
- Journal
- JAMA Surgery
- Published
- 2025-09-17
- DOI
- https://doi.org/10.1001/jamasurg.2025.3590
- Citations
- 25
- Primary Topic
- Bariatric Surgery and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 50.16